Literature DB >> 16237770

High concentration of antimitochondrial antibodies predicts progressive primary biliary cirrhosis.

Robert Flisiak1, Maria Pelszynska, Danuta Prokopowicz, Magdalena Rogalska, Urszula Grygoruk.   

Abstract

AIM: To evaluate the serum concentration of antimitochondrial antibodies (AMAs) as a prognostic indicator of progressive primary biliary cirrhosis (pPBC).
METHODS: Serum concentrations of AMA subtypes (anti-M2, anti-M4, and anti-M9), biochemical indices of liver function and Mayo risk factor (MRF) were determined in 30 women with diagnosed primary biliary cirrhosis (PBC) selected among 348 females with elevated alkaline phosphatase but without signs of hepatic decompensation. They were followed up for 5 years for possible development of hepatic decompensation.
RESULTS: Anti-M2 concentration was significantly correlated with bilirubin and albumin levels as well as MRF, whereas anti-M4 was significantly correlated with albumin level, prothrombin time and MRF. During the 5-year follow-up, progressive PBC (pPBC) was diagnosed in 3 among 23 patients available for evaluation. These 3 patients were positive for both anti-M2 and anti-M4. Anti-M2 serum concentration exceeded 1 300 RU/mL in patients with pPBC and only in 1 among 20 non-progressive PBC persons (5%). Anti-M4 serum concentration exceeded 400 RU/mL in 2 of the progressive patients and none in the non-progressive group. In contrast, anti-M9 serum concentration was below 100 RU/mL in all patients with pPBC, and higher than 100 RU/mL in 11 women (55%) among the non-progressive group.
CONCLUSION: Females with elevated alkaline phosphatase and high anti-M2 and anti-M4 concentrations are at a high risk for developing pPBC. Quantitative AMA detection should be considered as a method for early diagnosis of pPBC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16237770      PMCID: PMC4481493          DOI: 10.3748/wjg.v11.i36.5706

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  The follow-up of asymptomatic persons with antibodies to pyruvate dehydrogenase in adult population samples.

Authors:  K E Kisand; K Metsküla; K V Kisand; T Kivik; M E Gershwin; R Uibo
Journal:  J Gastroenterol       Date:  2001-04       Impact factor: 7.527

2.  Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases practice guidelines.

Authors:  E J Heathcote
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

3.  Is serum bilirubin concentration the only valid prognostic marker in primary biliary cirrhosis?

Authors:  P Krzeski; W Zych; E Kraszewska; B Milewski; E Butruk; A Habior
Journal:  Hepatology       Date:  1999-10       Impact factor: 17.425

4.  Prognosis in primary biliary cirrhosis: model for decision making.

Authors:  E R Dickson; P M Grambsch; T R Fleming; L D Fisher; A Langworthy
Journal:  Hepatology       Date:  1989-07       Impact factor: 17.425

5.  Epidemiology and natural history of primary biliary cirrhosis in a US community.

Authors:  W R Kim; K D Lindor; G R Locke; T M Therneau; H A Homburger; K P Batts; B P Yawn; J L Petz; L J Melton; E R Dickson
Journal:  Gastroenterology       Date:  2000-12       Impact factor: 22.682

6.  Survival probabilities of Pugh-Child-PBC classified patients in the euricterus primary biliary cirrhosis population, based on the Mayo clinic prognostic model. Euricterus Project Management Group.

Authors:  Y Reisman; G M van Dam; C H Gips; S M Lavelle; P M Euricterus
Journal:  Hepatogastroenterology       Date:  1997 Jul-Aug

7.  Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients.

Authors:  Christophe Corpechot; Fabrice Carrat; Raoul Poupon; Renee-Eugenie Poupon
Journal:  Gastroenterology       Date:  2002-03       Impact factor: 22.682

Review 8.  The epidemiology of primary biliary cirrhosis.

Authors:  Martin I Prince; Oliver F W James
Journal:  Clin Liver Dis       Date:  2003-11       Impact factor: 6.126

9.  Anti-M4 antibodies measured by a sulphite oxidase ELISA in patients with both anti-centromere and anti-M2 antibodies.

Authors:  C C Bunn; M McMorrow
Journal:  Clin Exp Immunol       Date:  1995-10       Impact factor: 4.330

Review 10.  Epidemiology and pathogenesis of primary biliary cirrhosis.

Authors:  Carlo Selmi; Pietro Invernizzi; Emmet B Keeffe; Ross L Coppel; Mauro Podda; Lorenzo Rossaro; Aftab A Ansari; M Eric Gershwin; Emmet B Keefe
Journal:  J Clin Gastroenterol       Date:  2004-03       Impact factor: 3.062

View more
  1 in total

1.  Clinical significance of IgG antimitochondrial M2 antibody levels in primary biliary cholangitis: A single center study from China.

Authors:  Lina Feng; Kaihui Dong; Xiaoxue Zhang; Bo Ma; Lin Chen; Qianqian Yang; Qingling Chen; Xiaoyu Wen; Qinglong Jin
Journal:  PLoS One       Date:  2020-11-12       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.